Navigation Links
VIRxSYS Presents Data on HIV Vaccine at Keystone HIV Vaccine Symposia
Date:3/28/2008

ing the massive destruction of CD4 T cells, and also to halt the subsequent slow destruction of the immune system by the latently dormant virus. Individuals will be protected but not totally sterilized, minimizing the likelihood of new infections.

"The use of a HIV-based lentiviral vector represents a truly innovative approach to anti-HIV vaccine and to all vaccination strategies in general. With VRX1023 in particular, we are turning HIV against itself. We are exploiting the virus ability to efficiently produce proteins for vaccination purposes," said Riku Rautsola, PhD, President and CEO of VIRxSYS. "VRX1023 presents us with a renewed hope for the delivery of an anti-HIV vaccine."

About VIRxSYS

VIRxSYS is a private biotechnology company using proprietary lentiviral vector delivery and RNA payload platforms to develop therapies for serious human diseases. The Company's initial lentiviral delivery technology was exclusively licensed from The Johns Hopkins University and has been substantially advanced in the Company's laboratories. The RNA payload technology was acquired and has been integrated with the Company's lentiviral delivery technology. In addition to preclinical programs for genetic and other serious diseases, the Company is currently developing gene and vaccine therapies for HIV, one of which, VRX496, has advanced to Phase 2 human clinical trials. More information regarding VIRxSYS can be found at http://www.virxsys.com. Details for the Phase II study can be found at the NIH clinical trials website at clinicaltrials.gov/show/NCT00131560.

Contact: Jeneane Smith / Russell LaMontagne

Phone: 212.255.5340


'/>"/>
SOURCE VIRxSYS
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014  Valeant Pharmaceuticals International, ... today announced it has completed the sale to Galderma ... Dysport owned or held by Valeant for $1.4 billion ... Nestle S.A, which recently completed its acquisition of Galderma. ... divestiture of our products to a company that is ...
(Date:7/10/2014)... 10, 2014  Decision Resources Group finds that ... (ID) specialists are willing to prescribe Durata,s Dalvance ... use as OPAT, approximately two-thirds of the respondents ... their hospital inpatients. However, our findings indicate that ... initiated on OPAT following hospital discharge, and most ...
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
Breaking Medicine Technology:Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 2Long-Acting Antibiotics Offering Once-Weekly Dosing Will See Favorable Uptake and Use as Outpatient Parenteral Antimicrobial Therapy (OPAT) 3
... , ATLANTA, Nov. 30 Amoena USA Corporation, ... the 4th Annual Breast Cancer Survivors Cruise. In 2010, for ... who helped them through their recovery by awarding a cabin ... , As part of the contest, Amoena wants to hear ...
... , ... the world,s leading research and advisory firms focusing on pharmaceutical ... market in Russia will grow nine percent annually over the ... This growth will be driven mainly by increased government spending ...
Cached Medicine Technology:Amoena and Young Survival Coalition Celebrate Breast Cancer Survivors With Contest and Cruise 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 2Russia's Hepatitis C Virus Drug Market Will Grow Nine Percent Annually, Reaching $327 Million by 2013 3
(Date:7/12/2014)... Sean Francis, owner of the Kawartha Lakes Fit Body ... clients. He’s also known for his support of local non-profits like ... combine the two and is excited to announce that his ... Girls Club. , The funds are the result of Francis’ 21-Day ... sent out emails and asked his clients to put out the ...
(Date:7/12/2014)... July 12, 2014 With prom shopping ... manufacturer and retailer, is ready to showcase its new ... new collection of evening dresses in its online shop. ... 67% off) for these elegant gowns. According to the ... end on July 26, 2014. , He says, ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 Doylestown Hospital ... a variety of men’s health questions. Paddock tackles ... to men, why women live longer than men, and ... Men's Health Made Simple featured on Doylestown Hospital’s ... a hernia at any age. If you notice pain, ...
(Date:7/12/2014)... A recent article released by Seattle's well known plastic surgeon, ... seeking cosmetic surgical procedures in summer months . ... begins to enliven the rainy Pacific Northwest, many people are ... didn’t work out as much during the winter as they ... of people eager to look their best for their summer ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 ... score of 4.1 out of 5. This above-average ... have been underpinning buyer negotiation power over the ... analyst Anna Son, “during the period, surging demand ... costs associated with new product development, have placed ...
Breaking Medicine News(10 mins):Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 2Health News:Kawartha Lakes Fit Body Boot Camp’s Successful Fat Loss Challenge Results in $2,000 to Boys and Girls Club 3Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4
... and its partner Hyderabad-based Biological E. Ltd. announced ... a pediatric phase II clinical trial for Intercell’s ... ,The randomized and controlled study aims to demonstrate ... vaccine compared to a locally produced mouse-brain Japanese ...
... the U.S. population. Nearly one-third of affected people have ... do not work well. Those who suffer from it ... biofeedback treatment can successfully retrain muscles. ,The biofeedback ... and exercise or another treatment (sham) that included muscle ...
... Responding to calls for a fair distribution of bird ... to create a global stockpile of vaccines// for developing ... great importance in the fight against avian influenza, WHO ... The Jakarta Post Thursday. ,Chan met President ...
... and Wales have been accused of being institutionally racist. ... although services are pioneers in moving towards equity, they ... challenges of a multi-cultural society. ,The "Count ... Commission, makes grim reading for people of African and ...
... during a recent influenza B epidemic in Japan showed ... drugs//, according to a study. ,Two antiviral ... drugs known as neuraminidase inhibitors, have been effective against ... evidence of the emergence of oseltamivir-resistant type A viruses, ...
... ruling in Alberta empowers pharmacists to prescribe medicines to ... will be allowed to take a decision on the ... or prescriptions given by doctors. ,Though this ... about the ability of the pharmacists to diagnose medical ...
Cached Medicine News:Health News:Biofeedback Treats One Type Of Chronic Constipation 2Health News:Biofeedback Treats One Type Of Chronic Constipation 3Health News:Chances of Tackling Racism in Mental Health Care is Still Remote 2Health News:Study Suggests Some Drug Resistance to Influenza B Medications 2
... is a low profile implantable bipolar ... stimulation of either the atrium (preformed ... model). All ZY leads are supplied ... used to extend/retract the fixation helix ...
... are small profile endocardial permanent pacing leads ... lead body size of only 4.8 F ... F, the Physique lead is the smallest ... in both straight and pre-formed J configurations, ...
Used with Temporary Myocardial Heartwires....
Used with permanent pacing leads....
Medicine Products: